Fresenius

Fresenius is pushing ahead with the expansion of its biopharma business: biopharma revenue grew organically almost 30% in the third quarter to €296 million, Kabi generated €2.3 billion in total, and currency‑adjusted EBIT rose to €391 million. With exclusive access to up to 37 biosimilar candidates from WuXi and the acquisition of Mabxience, the portfolio is to be expanded to as many as 66 molecules by 2030, with the aim of being among the top three providers by 2035. The group increased quarterly sales to around €5.8 billion (+5%) and reported currency‑adjusted core earnings per share of €0.72; for 2026 the company remains committed to a revenue forecast of 4–7% growth. » More on faz.net

Fresenius now expects currency-adjusted core earnings per share growth in the upper half of the 10–15% range and an EBIT margin above 11.5% for 2026. In the quarter, sales rose 6% to €5.8 billion, EBIT grew 11% to €638 million, and core earnings per share increased organically by 14%. Drivers were hospital subsidiary Helios and the Kabi division, notably the biosimilars business, which grew organically by 29%; additionally, a partnership with WuXi Biologics secures access to up to 37 further candidates. Net financial debt fell slightly to around €10.1 billion and return on invested capital (ROIC) reached 7.0%, the highest level in ten years. » More on manager-magazin.de

Fresenius reports a strong third quarter: revenue rose 6% to €5.8 billion. Adjusted earnings per share, currency-adjusted, climbed to €0.72 (+14% currency-adjusted) and adjusted EBIT increased nominally by 11% to €638 million; adjusted group net income grew 15% to €403 million. CEO Michael Sen says the company is on track and now expects adjusted core earnings per share growth, currency-adjusted, to be in the upper half of the 10–15% target range. » More on wiwo.de

Fresenius has agreed a ten-year development partnership with WuXi Biologics, potentially gaining access to up to 37 additional biosimilar candidates and expanding its portfolio from 29 to as many as 66 products. Target markets include originator drugs with a volume of more than €370 billion; initial focus will be on biosimilars for Polivy and Tepezza. The deal foresees milestone-based payments tied to development progress instead of large upfront fees and is intended to make the company less dependent on its dialysis and hospital businesses. CEO Michael Sen expects the first product launches in the early 2030s; Fresenius plans to fund the costs from ongoing operations and not to take on new debt. » More on n-tv.de

Jefferies analyst James Vane-Tempest keeps his rating on Fresenius at buy and names a price target of 55 euros. The cooperation with WuXi Biologics could expand the biosimilars portfolio from 29 to 66 molecules and, according to a study, addresses a market potential of 370 billion euros. After the publication, the Fresenius share rose intraday by around 2.9% to 49.17 euros, with the price target signaling an upside potential of about 11.9%. » More on finanzen.net